Merck & Co., Inc. (NYSE:MRK) Position Raised by Parkside Financial Bank & Trust

Parkside Financial Bank & Trust increased its position in shares of Merck & Co., Inc. (NYSE:MRK) by 7.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 15,909 shares of the company’s stock after buying an additional 1,168 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Merck & Co., Inc. were worth $1,339,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in MRK. Nuveen Asset Management LLC raised its holdings in Merck & Co., Inc. by 6,517.4% during the second quarter. Nuveen Asset Management LLC now owns 24,307,332 shares of the company’s stock worth $2,038,169,000 after purchasing an additional 23,940,007 shares in the last quarter. BlackRock Inc. raised its holdings in Merck & Co., Inc. by 2.3% during the second quarter. BlackRock Inc. now owns 191,863,408 shares of the company’s stock worth $16,087,745,000 after purchasing an additional 4,397,580 shares in the last quarter. Invesco Ltd. raised its holdings in Merck & Co., Inc. by 18.4% during the second quarter. Invesco Ltd. now owns 18,309,138 shares of the company’s stock worth $1,535,222,000 after purchasing an additional 2,843,458 shares in the last quarter. Schroder Investment Management Group raised its holdings in Merck & Co., Inc. by 67.7% during the second quarter. Schroder Investment Management Group now owns 6,381,329 shares of the company’s stock worth $535,075,000 after purchasing an additional 2,576,060 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its holdings in Merck & Co., Inc. by 20.4% during the second quarter. UBS Asset Management Americas Inc. now owns 11,661,412 shares of the company’s stock worth $977,809,000 after purchasing an additional 1,972,587 shares in the last quarter. 74.95% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE MRK traded up $0.71 during trading on Friday, hitting $83.59. The company had a trading volume of 6,053,527 shares, compared to its average volume of 10,105,755. The company has a market cap of $212.31 billion, a P/E ratio of 19.26, a PEG ratio of 1.80 and a beta of 0.54. Merck & Co., Inc. has a 52 week low of $70.89 and a 52 week high of $87.35. The business’s 50-day moving average is $84.01 and its 200 day moving average is $82.77. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.24 by $0.27. The company had revenue of $12.40 billion for the quarter, compared to analysts’ expectations of $11.59 billion. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The firm’s revenue was up 14.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.19 earnings per share. On average, research analysts expect that Merck & Co., Inc. will post 5.16 EPS for the current year.

MRK has been the topic of several recent analyst reports. Mizuho boosted their target price on Merck & Co., Inc. from $97.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Societe Generale set a $105.00 target price on Merck & Co., Inc. and gave the stock a “buy” rating in a report on Tuesday, September 3rd. JPMorgan Chase & Co. set a $96.00 price target on Merck & Co., Inc. and gave the company a “buy” rating in a report on Thursday, October 10th. Leerink Swann initiated coverage on Merck & Co., Inc. in a report on Thursday, August 15th. They issued an “outperform” rating and a $103.00 price target on the stock. Finally, Svb Leerink initiated coverage on Merck & Co., Inc. in a report on Friday, August 16th. They issued an “outperform” rating and a $103.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating to the company. Merck & Co., Inc. presently has a consensus rating of “Buy” and a consensus price target of $95.13.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: Correction

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.